PubMed COVID-19 Clinical Care

CONCLUSIONS: Tocilizumab improves clinical outcomes in hospitalized COVID-19 patients. These advantages were evident independent of the patient's comorbidities and were in addition to the advantages of systemic corticosteroids. In COVID-19 patients

Are people more or less likely to follow numerical advice that communicates uncertainty in the form of a confidence interval? Prior research offers competing predictions. Although some research suggests that people are more likely to follow the

The overarching goal of the Australian coronavirus disease 2019 (COVID-19) vaccination program has been to protect all people in Australia from the harm caused by the novel coronavirus SARS-CoV-2. This review reflects on the role of the Australian

Quantifying the spreading power of a pandemic like COVID-19 is important for the early implementation of early restrictions on social mobility and other interventions to slow its spread. This work aims to quantify the power of spread, defining a new

No abstract

Cytomegalovirus (CMV) infection is a major driver of accelerated immunosenescence related to CD28null T cells expansion. CMV infection and these proatherogenic T cells have been independently associated with cardiovascular disease and COVID-19

As infected and vaccinated population increases, some countries decided not to impose non-pharmaceutical intervention measures anymore and to coexist with COVID-19. However, we do not have a comprehensive understanding of its consequence, especially

Chronic inflammatory gastrointestinal diseases such as Crohn's disease (CD) and ulcerative colitis (UC) are known as inflammatory bowel disorders (IBD). Patients with inflammatory bowel illnesses are more susceptible to viral infections. In people

The COVID-19 pandemic has exposed serious shortcomings in healthcare systems around the world. Shortages of staff, equipment and access to healthcare have created major obstacles for facilities when managing public health emergencies. The pandemic

We experienced a case of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis after Moderna COVID-19 vaccination. An 82-year-old woman developed pyrexia and general malaise one month after her third booster vaccine